Biotherapeutics

#Biotherapeutics #Cancer immunotherapy #Cancer research #Chemotherapy #Oncology #Therapeutics

Study could combat aggressive chemotherapy resistant TNBC

A Mount Sinai study titled Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease describes how a novel therapeutic (108600) combats aggressive chemotherapy-resistant triple-negative breast cancer (TBNC). 108600 targets and inhibits breast cancer stem cells, a subpopulation of cells found within patient triple negative… Read More

#Editor's Choice #News

#Biotechnology #Biotherapeutics #Market reporting

Innovation and opportunity within Europe’s biotech sector

Listen to this article on the DDW Podcast: Lu Rahman introduces a slice of European biotech expertise Thanks to the Covid-19 pandemic, the global biotech sector has been thrown into the spotlight, not just in the drug discovery and development word, but as a sector that the general public has come… Read More

#Editor's Choice #Exclusive Content #Intelligence #Market Reports #News #Opinion #Trends & Analysis

#Antibodies #Biopharmaceuticals #Biotherapeutics #Covid-19 #SARS-CoV-2

Helping Indian biotherapeutic companies advance novel therapeutics

Fusion Antibodies and BioTickle, its distributor in India, are providing local biopharmaceutical organisations with access to biopharmaceutical development capabilities. Since the emergence of Covid-19, Fusion Antibodies has contributed resources into developing a panel of unique protein antigens for use in discovery platforms. To date, the proteins have shown positive profiles… Read More

#News

#Biotherapeutics #Clinical trials #Drug development #Drug discovery #Pharma #Rare disease

This week in drug discovery (19 – 23 July)

News round-up by DDW’s Megan Thomas for 19 – 23 July DDW’s Megan Thomas rounds up her top five stories this week which facilitate the continuation of vital drug discovery research, from partnerships and funding to successful trials and informative reports. Exscientia accelerates Covid-19 drug discovery using AI Exscientia… Read More

#News #Trending News

#Biotherapeutics #Drug development #Parkinson's

Innovative CNS medicines partnership announced

Bial and Medis have partnered on two of Bial’s proprietary drugs: Zebinix (eslicarbazepine acetate) and Ongentys (opicapone). The established partnership comprises an exclusive distribution agreement for Zebinix in the Czech Republic and Slovakia and an exclusive distribution agreement for Ongentys in Bosnia and Herzegovina, Bulgaria, Croatia, the Czech Republic, Estonia,… Read More

#News

#Biotherapeutics #Clinical research #Microbiome #Therapeutics

Report reveals the potential of microbiome-targeting therapeutics

GlobalData’s report, ‘Thematic Research: Microbiome-Targeted Therapeutics in Immunology’, reveals that 23 microbiome-targeting therapeutics are currently being developed in the US and the 5EU (France, Germany, Italy, Spain, UK) for gastrointestinal (GI), dermatological, and respiratory conditions. Each of these therapies aims to address these diseases by manipulating the microbiome. Microbiome is… Read More

#Market Reports #News #Trends & Analysis

#Biotherapeutics #Clinical trial #Clinical Trial Authorisation #Drug delivery #Drug development #Therapeutics

FDA Fast Track designation for Parkinson’s Disease treatment

BlueRock Therapeutics has been granted Fast Track designation by the US Food and Drug Administration (FDA) for DA01 for advanced Parkinson’s disease (PD). DA01, BlueRock’s pluripotent stem cell-derived dopaminergic neuron therapy, is under evaluation in a Phase I study. “Receiving Fast Track Designation from the FDA is an important step,… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Biotherapeutics #Covid-19 #Drug design #Drug development #Therapeutics

Exscientia accelerates Covid-19 drug discovery using AI

Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the Covid-19 Therapeutics Accelerator initiative, to progress a new class of Covid-19 therapeutics created using its artificial intelligence (AI) drug design platform. Exscientia has demonstrated proof-of-concept by using its AI platform… Read More

#News

#Biotherapeutics #Clinical trials #Drug development #Drug discovery #Pharma #Rare disease

This week in drug discovery (5 – 9 July)

News round-up by DDW’s Megan Thomas for 5 – 9 July We know that innovation is key in the drug discovery and development sector. DDW’s Megan Thomas rounds up her top five stories this week which highlight the industry’s on-going work to create breakthrough therapeutics for global wellbeing. Read More

#News #Trending News

#Biotechnology #Biotherapeutics #Clinical trials #Therapeutics

Starton Therapeutics features on Amazon Prime ‘Unicorn Hunters’

‘Unicorn Hunters’ is a new show on Amazon Prime which invites viewers around the world to invest alongside a panel of entrepreneurs and business leaders. It aims to level the field for start-ups who do not have access to traditional venture capital funding. The panel includes Steve Wozniak (Co-founder of… Read More

#News

#Biosciences #Biotherapeutics #Drug design #Drug development #Drug discovery

New approach will help identify drugs that can ‘glue’ proteins together

A new screening method that can test the effectiveness of therapeutic molecules designed to ‘glue’ proteins together in the body has been developed by researchers at the University of Birmingham and the University of Leicester. The research paves the way for drug developers to screen large numbers of potential new… Read More

#Editor's Choice #News

#Biotherapeutics #Clinical trials #Drug discovery #Life sciences

Awakn Life Sciences: new CRO and patent application

Awakn Life Sciences has appointed neuroscientist and addiction researcher, Professor David Nutt as Chief Research Officer as well as announcing the filing of patent applications in the US for two next-generation novel MDMA-derived new chemical entities. This executive appointment is driven by the expansion of Awakn’s psychedelic drug and therapy… Read More

#News

#Antibodies #Biotherapeutics #Clinical trial

IONTAS collaboration with F-star enters clinical trial

F-star Therapeutics has dosed the first patients in a Phase I clinical trial, with FS222, a CD137/PD-L1 bispecific antibody. IONTAS applied its proprietary technology to generate a component utilised within FS222, which was subsequently licenced to F-star. António Parada, CEO at IONTAS, commented: “We are delighted with the progress of… Read More

#News

#Biotherapeutics #Cancer research #CAR-T #Cell therapy #Clinical trials #Drug development

Aleta and Cancer Research UK to advance blood cancer therapy

Aleta Biotherapeutics and Cancer Research UK have collaborated to advance the early phase clinical development of Aleta’s CAR-T cell engager candidate, ALETA-001. Under the terms of the clinical development partnership, Cancer Research UK’s Centre for Drug Development will fund, sponsor and conduct the first-in-human Phase I/IIa clinical trial of ALETA-001,… Read More

#News

#Biologics / Biotechnology #Biotherapeutics #Podcast

Expertise on quantitative analysis of product purity – podcast

In the latest sponsored DDW podcast, discover how accurate and quantitative analysis of product purity is a fundamental for effective development of biotherapeutic proteins. This episode features DDW Editor in Chief  Lu Rahman and Tufan Aydogdu, Field Applications Manager of ProteinSimple, a Bio-Techne brand. Aydogdu talks Lu through how the… Read More

#News

#Biotherapeutics #Podcast #Sitting Down With

Comparing SDS-PAGE with automated CE-SDS for improved quantitation, reproducibility, and faster sample turn-around time

The latest DDW Sponsored Sitting Down With podcast features Tufan Aydogdu, Field Applications Manager, ProteinSimple, a Bio-Techne brand. Dr. Aydogdu talks us through how the accurate and quantitative analysis of product purity is a fundamental component of effective development of a biotherapeutic protein. But without consistent techniques and high-quality,… Read More

#Podcasts